» Articles » PMID: 24279589

Interface Dynamics Explain Assembly Dependency of Influenza Neuraminidase Catalytic Activity

Overview
Date 2013 Nov 28
PMID 24279589
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Influenza virus neuraminidase (iNA) is a homotetrameric surface protein of the influenza virus and an established target for antiviral drugs. In contrast to neuraminidases (NAs) of other biological systems (non-iNAs), enzymatic activity of iNA is only observed in a quaternary assembly and iNA needs the tetramerization to mediate enzymatic activity. Obviously, differences on a molecular level between iNA and non-iNAs are responsible for this intriguing observation. Comparison between protein structures and multiple sequence alignment allow the identification of differences in amino acid composition in crucial regions of the enzyme, such as next to the conserved D151 and the 150-loop. These differences in amino acid sequence and protein tetramerization are likely to alter the dynamics of the system. Therefore, we performed molecular dynamics simulations to investigate differences in the molecular flexibility of monomers, dimers, and tetramers of iNAs of subtype N1 (avian 2004, pandemic 1918 and pandemic 2009 iNA) and as comparison the non-iNA monomer from Clostridium perfringens. We show that conformational transitions of iNA are crucially influenced by its assembly state. The protein-protein interface induces a complex hydrogen-bonding network between the 110-helix and the 150-loop, which consequently stabilizes the structural arrangement of the binding site. Therefore, we claim that these altered dynamics are responsible for the dependence of iNA's catalytic activity on the tetrameric assembly. Only the tetramerization-induced balance between stabilization and altered local flexibility in the binding site provides the appropriate arrangement of key residues for iNA's catalytic activity.

Citing Articles

Pyrrolo[2,3-]indazole as a novel chemotype for both influenza A virus and pneumococcal neuraminidase inhibitors.

Egorova A, Richter M, Khrenova M, Dietrich E, Tsedilin A, Kazakova E RSC Adv. 2023; 13(27):18253-18261.

PMID: 37350858 PMC: 10282731. DOI: 10.1039/d3ra02895j.


Co-infection of the respiratory epithelium, scene of complex functional interactions between viral, bacterial, and human neuraminidases.

Escuret V, Terrier O Front Microbiol. 2023; 14:1137336.

PMID: 37213507 PMC: 10192862. DOI: 10.3389/fmicb.2023.1137336.


Binding mechanism of oseltamivir and influenza neuraminidase suggests perspectives for the design of new anti-influenza drugs.

Tao J, Wang H, Wang W, Mi N, Zhang W, Wen Q PLoS Comput Biol. 2022; 18(7):e1010343.

PMID: 35901128 PMC: 9401145. DOI: 10.1371/journal.pcbi.1010343.


Pre-existing antibodies directed against a tetramerizing domain enhance the immune response against artificially stabilized soluble tetrameric influenza neuraminidase.

Catani J, Job E, Ysenbaert T, Smet A, Ray S, LaRue L NPJ Vaccines. 2022; 7(1):11.

PMID: 35087067 PMC: 8795415. DOI: 10.1038/s41541-022-00435-7.


Optimisation of Neuraminidase Expression for Use in Drug Discovery by Using HEK293-6E Cells.

Campbell A, Tanner J, Krause K Viruses. 2021; 13(10).

PMID: 34696326 PMC: 8538103. DOI: 10.3390/v13101893.


References
1.
Davies G, Henrissat B . Structures and mechanisms of glycosyl hydrolases. Structure. 1995; 3(9):853-9. DOI: 10.1016/S0969-2126(01)00220-9. View

2.
Wang J, Wolf R, Caldwell J, Kollman P, Case D . Development and testing of a general amber force field. J Comput Chem. 2004; 25(9):1157-74. DOI: 10.1002/jcc.20035. View

3.
Winger M, von Itzstein M . Exposing the flexibility of human parainfluenza virus hemagglutinin-neuraminidase. J Am Chem Soc. 2012; 134(44):18447-52. DOI: 10.1021/ja3084658. View

4.
Hashimoto K, Panchenko A . Mechanisms of protein oligomerization, the critical role of insertions and deletions in maintaining different oligomeric states. Proc Natl Acad Sci U S A. 2010; 107(47):20352-7. PMC: 2996646. DOI: 10.1073/pnas.1012999107. View

5.
Ali M, Imperiali B . Protein oligomerization: how and why. Bioorg Med Chem. 2005; 13(17):5013-20. DOI: 10.1016/j.bmc.2005.05.037. View